O B J E C T I V E : To assess the 2012 served available market for tuberculosis (TB) diagnostics in China in the sector served by the China Centre for Disease Control and Prevention (CDC) and the hospital sector in China, including both designated TB hospitals and general hospitals. D E S I G N : Test volumes and unit costs were assessed for tuberculin skin tests, interferon-gamma release assays (IGRAs), smear microscopy, serology, cultures, speciation tests, nucleic-acid amplification tests (NAATs), drug susceptibility tests and adenosine-deaminase tests (ADA). Data were obtained from electronic databases (CDC sector) and through surveys (hospital sector), and were estimated for the two sectors and for the country as a whole. Test costs were estimated by staff at China CDC, and using published literature. R E S U LT S : In 2012, the China CDC and hospital sectors performed a total of 44 million TB diagnostic tests at an overall value of US$294 million. Tests used by the CDC sector were smear microscopy, solid and liquid culture and DST, while the hospital sector also used IGRAs, NAATs, ADA and serology. The hospital sector accounted for 76% of the overall test volume and 94% of the market value. C O N C L U S I O N : China has a very large TB diagnostic market that encompasses a wide range of diagnostic tests, with the majority being performed in Chinese hospitals. K E Y W O R D S : tests; costs; volumes; diagnosis TUBERCULOSIS (TB) remains a major global public health problem, with 9 million incident cases and 1.5 million deaths in 2013. 1 One of the main barriers to effective TB control is timely and accurate diagnosis. Almost 3 million TB cases and three quarters of multidrug-resistant TB (MDR-TB) cases were estimated to have remained undiagnosed in 2013. 1 Despite progress in the development of new technologies, many countries still rely on poorly sensitive smear microscopy for TB detection. 2 There remains an urgent need for more sensitive, affordable and rapid diagnostic tests for TB. 3 To encourage TB diagnostics research and development, the Foundation for Innovative New Diagnostics (FIND) and The Special Programme for Research and Training in Tropical Diseases published a global market assessment for TB diagnostics in 2006. 4 This report showed that globally over one billion US dollars (USD) was spent annually on TB diagnostics. Almost a decade later, much has changed in the diagnostics world, with many World Health Organization (WHO) approved new technologies entering the market. 3, 5 There is a need to capture the current market for TB diagnostics, especially with a focus on the emerging markets such as the BRICS (Brazil, Russia, India, China, South Africa) countries, which account for 46% of the estimated global TB burden. Updated market analyses for Brazil and South Africa have recently been completed by our Consortium. 6, 7 China, the world's most populous country with the second largest economy in the world, provides promising potential for the development and use of new TB diagnostics. China has the second largest number of TB cases worldwide after India, and has reported high rates of drug-resistant TB. 8 In 2012, there were a total of 900 678 notified TB cases in China, which accounted for 15% of global notified cases for that year. Furthermore, it was estimated that there were 60 000 cases of MDR-TB, accounting for 13.3% of the global burden. 1 In recent years, China has made great strides in TB control by attaining the 2005 global targets for TB control, a 70% detection rate and an 85% cure rate. A high level of political commitment and leadership has been demonstrated by major increases in the Correspondence to: Sandra V Kik, KNCV Tuberculosis Foundation,
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METHODS
Setting TB control institutions in China include TB dispensaries, and hospitals designated by local health authorities to provide TB care (designated hospitals). First, there are TB dispensaries, which are responsible for case detection and treatment. The National TB Control and Prevention Guide (2011-2015) 14 mandates the TB dispensaries to carry out case management and follow-up as well as TB-related education. There are approximately 3490 dispensaries established at four vertical levels: national, provincial, prefectural and county. 15 Second, designated hospitals provide testing and treatment services. These include TB hospitals, chest/pulmonary hospitals, infectious disease hospitals, and general hospitals with a TB clinic. 16 Non-designated general hospitals (referred to here as general hospitals) are the first point of health care entry for most patients. A TB diagnosis cannot be confirmed, nor can presumptive TB patients be treated at a general hospital, which requires referral to TB control institutions and reporting of all presumed cases through the CISDCP. 13, 14 The 2010 National Tuberculosis Prevalence Survey found that general hospitals were the most common point of health care entry, where 56.2% of TB patients first reported for care. 11 The recommended diagnostic algorithm for pulmonary TB (PTB) in adults in China is shown in Appendix Figure A.* 17 Briefly, patients with suspected PTB undergo a chest X-ray and provide three sputum smears. Where laboratory capabilities exist, culture is performed on at least two specimens. Interferon-gamma release assays (IGRAs) are used as ancillary tests in China for the diagnosis of active PTB as well as for the detection of latent tuberculous infection (LTBI). 14 For the detection of drug-resistant TB, drug susceptibility testing (DST) is recommended for re-treatment sputum smear-positive TB patients, chronic TB patients, patients with treatment failure, and new patients who are still sputum smear-positive after 3 months of treatment. 17 TB diagnosis, including chest X-ray examination and smear microscopy at the first visit, as well as anti-tuberculosis drugs for up to 8 months, are provided free of charge by TB control institutes. 17, 18 Tests included in this market assessment Data on the volume of tests performed and the cost per test for the year 2012 were collected for the China CDC and hospital sectors for all diagnostics used for the detection of LTBI, for the initial diagnosis of active TB and for follow-up testing, and for DST. These included tuberculin skin tests (TSTs), IGRAs, serology (over 20 commercial antibody-based rapid and enzyme-linked immunosorbent assays are available on the Chinese market 19 ), sputum smear microscopy (SSM), solid and liquid culture, and nucleic-acid amplification tests (NAATs) such as polymerase chain reaction (PCR) and line-probe assays (LPAs), Mycobacterium tuberculosis speciation tests, phenotypic DST and the adenosine deaminase test (ADA). Although the Xpert w MTB/ RIF assay (Cepheid Inc, Sunnyvale, CA, USA) is currently used in China, it had not yet been approved for routine use in 2012 and was therefore not included in this analysis.
Methods used for calculation of test volumes
As described in detail in our previous analyses for Brazil 7 and South Africa, 6 three methods were used to estimate test volumes. A bottom-up method was used for volumes of tests used in the CDC sector for which data were retrieved from the database of the National Tuberculosis Reference Laboratory of China. This represented the test volumes for all TB dispensaries.
Test volumes in both the designated and general hospitals were estimated using a middle-out approach, in which survey results from a representative sample of hospitals were extrapolated to estimate the total volume for this sector. This approach was used in designated hospitals and general hospitals for test volumes and prices charged. Structured question-naires were sent out to 18 designated hospitals at provincial (n ¼ 6), prefectural (n ¼ 6) and county (n ¼ 6) levels. Two sample sites from East, Central and West China were chosen at each level. As no data were available on the number of hospitals designated for TB, we conservatively estimated that there was only one designated hospital per city (whereas there might in fact have been more than one for some cities), at the provincial and prefectural levels (34 province-level cities, 345 prefecture-level cities 20 ), and roughly one designated hospital in 25% of all county-level cities (CDC internal data). According to the National TB Control and Prevention Guide (2011) (2012) (2013) (2014) (2015) , China is in the process of transferring all TB care and services to designated TB hospitals. 14 To estimate the overall test volumes for all designated hospitals, survey results were extrapolated by multiplying the average numbers of tests performed in each region and respective administrative level by the corresponding number of estimated designated hospitals at each of these levels and regions.
To estimate the test volumes in general hospitals, the same survey was conducted in 60 general (i.e., nondesignated) hospitals, where hospitals were again stratified by their level as classified by the National Health and Family Planning Commission (NHFPC), 21 and their geographic locations. The national test volumes for general hospitals were estimated by multiplying the average numbers of tests from the surveyed hospitals by the estimated number of general hospitals at different geographic regions and levels, respectively. 15 Level 1 hospitals were excluded due to their limited laboratory capacity. 21 A top-down approach was used when database or survey data were not available, in which case test volume information was acquired from manufacturers. This method was used for the volume of IGRAs and the number of pyrazinamide (PZA) DST tests used in the hospital sector.
As data collection was based on aggregated programme data in which individual persons were not identifiable, no ethics approval was sought.
Methods used for the calculation of test costs in China
All costs (from a health system perspective) and prices are presented in 2012 USD. Costs and prices were collected in Chinese renminbi (RMB) and converted into USD using the World Bank official exchange rate for 2012 (6.31:1). 22 Most TB tests provided by the China CDC sector are free of charge for TB patients. To have a realistic estimate of the actual costs for TB tests performed in the CDC sector, the unit costs were determined by a components approach, using the average costs for reagents and consumables, labour, equipment amortization and laboratory overheads, including water, electricity, security and building costs. These test costs were calculated by CDC staff using procurement cost data for reagents, consumables and equipment and interviews with laboratory staff to obtain information on the hands-on time per test. Per expert consensus, a standard overhead cost of 20% was applied.
As it was not possible to assess the highly variable costs of tests in the hospital sectors, the price charged per test was used for this sector. Due to governmentimposed pricing controls for health services and diagnostics in Chinese hospitals, the prices charged by hospitals for TB tests were in a designated range across the country. 23 We assessed the range of prices charged per test from the hospital surveys and from four provincial price bureaux, [24] [25] [26] [27] and used the mean of the range per test as the test prices for the hospital sector. These estimated prices were corroborated by in-country experts.
To estimate the national overall market value for TB diagnostics, including the CDC and hospital sectors, the CDC cost per test was used when the same test was performed in both sectors. For tests that were performed in hospitals only, unit costs were estimated by the CDC staff who perform the tests, except for the LPA, where cost was taken from a recent publication and adjusted for 2012. 28 When using the published test cost, data for the same components as described above were used, with adjustments made for the 2012 exchange rate and a 3% inflation rate per year. For serology and PCR, the hospital price charged per test was used in the calculation of the overall market value, as no reagent costs were available.
The SAM, defined as the total volume and value of TB diagnostics in China, was calculated for the country as a whole, and for the CDC and hospital sectors separately. Three different market values were calculated. First, the value of the CDC sector market was calculated by multiplying the volume of each test in the CDC sector by the CDC-estimated test costs. Second, the value of the hospital-sector market was calculated by multiplying the test volumes of the hospital sector (both designated hospitals and general hospitals) by the average hospital-sector price charged. Finally, the value of the overall TB diagnostic market was calculated by multiplying the total volume of each test performed in both sectors by the CDC sector cost or the unit cost estimated by CDC for tests performed solely in the hospital sector. All unit costs are presented in Table 1 .
Sensitivity analysis
A sensitivity analysis was performed to reflect variations in labour and overhead costs in different parts of the country and at different service levels. A sensitivity analysis was only performed for those diagnostic tests for which the breakdown of cost components was available. We calculated the variation in the hourly labour cost based on the maximum and minimum annual salaries across the country in 2013. According to National Bureau of Statistic of People's Republic of China, 29 the maximum and minimum of hourly wages (converted from annual salaries data) were 22.2% above and 10.8% below the average hourly wage, 22 RMB/h (US$3.44/h). We also searched the literature for costing studies in China to find a range for laboratory overhead costs. Previous studies reported overhead costs ranging from 15% to 25%, 28, [30] [31] [32] [33] which were used as our range of variation.
RESULTS

TB diagnostic test volumes and costs in the CDC sector
The volume of TB tests performed in the CDC sector in 2012 was 10.6 million tests at a value of US$18.1 million (Appendix Table A .2, Figures 1 and 2 ). SSM represented a volume of 10.3 million tests (97%), at a cost of US$13.4 million or 74% of the CDC sector market value. For culture, both solid and liquid media were used, for a total volume of 0.29 million tests and a value of US$3.3 million. DST (solid or liquid medium) contributed ,1% of testing in the CDC sector in 2012, and accounted for 8% of the market value in this sector. TST was not performed in the CDC sector in 2012 due to a reagent problem, and IGRAs were not used in this sector. CDC sector tests were used entirely for the diagnosis and follow-up of active TB.
TB diagnostic test volumes and market value at designated hospitals A total of 12 million tests were performed in 2012 in designated hospitals. When using the price charged per test the total value amounted to US$89 million (Appendix Table A .3, Figures 1 and 2) . The highest volumes of tests performed were SSM and serology, with 4.1 and 2.2 million tests performed, at a value of respectively 11.4 million and US$6.9 million. Firstand second-line DST accounted for 7% of the total test volume (0.8 million) and 23% of the total market value in designated hospitals (US$20 million). Culture, using solid and liquid media, represented a volume of 1.7 million tests at a value of US$12 million. A limited number of NAATs (LPA, microarray, PCRs) were performed in designated hospitals: 0.3 million tests at a value of US$14 million, 16% of the market value. For TST, 1.5 million tests were performed at a value of US$4 million.
TB diagnostic test volumes and market value in the general hospitals A total of 21 million tests were performed in general hospitals, amounting to an estimated value of US$170.5 million (Appendix Table A 
Served available overall market (both sectors) in China in 2012
Overall, an estimated total of 44 million tests were performed nationwide in the combined health sec- 34 The majority of TB diagnostic tests were performed in the hospital sector, and the market was more diverse in the designated hospitals than in the China CDC and the general hospitals. Designated and general hospitals together contributed 76% to the overall test volumes and 94% to the overall market value. The large market in the general hospitals was likely due to the large numbers of hospitals, and the fact that they are the most common first point of medical contact for notified TB patients. 11 The tests used in general hospitals were therefore predominantly SSM, and there was a lack of more complex tests, such as those used to detect drug resistance. Designated hospitals played an increasingly important role in TB diagnosis, as mandated by the 2011-2015 National TB policy. 14 Various TB tests were used in the designated hospitals, including DST and several of the latest WHO-endorsed tests to detect active TB as well as drug resistance. The fact that many of these tests were not included in the national diagnostic algorithm (Appendix Figure A) may encourage Chinese policy makers to revise the algorithm to create a standardised diagnostic process for TB in the designated hospitals.
Overall, TB diagnostic testing in China in 2012 still relied on a few conventional TB tests, predominantly SSM, which contributed more than half (62%) of the TB diagnostics market analysis: China overall test volumes. The second most commonly used TB test was serology, although the WHO has issued a policy against the use of serology for active TB. 35 The availability of a large number of commercial serological tests made in China 19 provides additional evidence of their popularity in China.
In terms of market value or expenditure, IGRAs accounted for 47% of the total market value, all of this outside the China CDC sector. While the WHO and the International Standards for TB Care have discouraged the use of IGRAs for active TB, 36 these tests are commonly used, and probably for active TB rather than LTBI screening. Again, the availability of domestic IGRAs by Chinese companies is a reflection of their growing popularity.
Several more sophisticated tests such as NAAT, culture and DST contributed little to the overall test volumes, at 1%, 5% and 2%, respectively. However, this will likely change as the next 5-year National Plan for TB has been set to expand culture to more than 80% of county TB laboratories and to provide DST and rapid speciation tests in all prefectural and provincial TB laboratories. 14 It is therefore expected that the market share for culture, DST and molecular tests will grow in the coming years.
A limitation of this study was the exclusion of chest X-rays (multipurpose use), blood culture and histopathology. It is also possible that the actual number of general hospitals was lower than our estimate, as accurate data on the number of general hospitals with TB clinics were not available. However, this overestimating effect was to a certain extent offset by the exclusion of Level 1 general hospitals. The number of designated hospitals may have exceeded our conservative estimate, as there may have been more than one designated hospital in some of the more affluent eastern provinces. Finally, the unit test costs may be different from our estimation in different regions across the country, similar to the variation in prices charged by different hospitals.
This analysis of the served available market for TB diagnostics in China in 2012 describes the volumes and costs of the various tests that were in use for the diagnosis of LTBI and active TB, DST and treatment follow-up, as well as their market division in the CDC and hospital sectors. This report will help test developers understand the current and potential market for new replacement or add-on TB diagnostic technologies in China. Se evaluaron los volúmenes y los costos unitarios de la prueba cutá nea de la tuberculina, las pruebas de liberación de interferón gama (IGRA), la baciloscopia, las pruebas serológicas, los cultivos, las pruebas de identificación de especie, las pruebas de amplificación de á cidos nucleicos (NAAT), las pruebas fenotípicas de sensibilidad a los medicamentos (DST) y las pruebas de determinación de la desaminasa de adenosina (ADA). Los datos se obtuvieron a partir de bases de datos electrónicas (en el sector de los CDC) y mediante encuestas (en el sector hospitalario) y se calcularon las cifras en ambos sectores y a escala nacional. La estimación de los costos de las pruebas se logró con la colaboración del personal de los CDC y los datos comunicados en las publicaciones científicas. R E S U LTA D O S: En el 2012, se practicaron en ambos sectores 44 millones de pruebas diagnósticas de la TB por un valor total de US$294. Las pruebas utilizadas en el sector de los CDC fueron la baciloscopia, los cultivos en medio sólido y medio líquido y las DST; en el sector hospitalario se practicaron ademá s las IGRA, NAAT, ADA y las pruebas serológicas. El sector hospitalario representó el 76% del volumen total de las pruebas y el 94% del valor comercial.
C O N C L U S I Ó N: La China cuenta con un vasto mercado para los medios diagnósticos de la TB, que comporta una amplia gama de pruebas diagnósticas, las cuales se practican en su mayor parte en los hospitales del país.
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